The factors in favour of a drop in the Ipsen share price:
Of course, although the strengths of the Ipsen company are many and lead us to believe in a future increase in its share price on the stock market, you should also be aware of the various weak points of the company and the disadvantages of this value. Here is a summary of the weaknesses of the Ipsen group.
Among the obstacles to the development of Ipsen, are the problems encountered in Europe, more specifically in France with regard to the end of the reimbursement of certain products. These measures lead to a net decline in sales for the community medicine sector and additional pressure on the pricing of these drugs.
Furthermore, the success and profitability of Ipsen is mainly based on 3 types of drugs which alone achieve more than 2/3 of sales. This dependence on only a few products exposes the group to certain risks.
Although we recognise the distribution of the Ipsen group's activities around the world, certain shortcomings concerning the American market are still weighing on its profitability. The group's presence in fact remains insufficient in the USA.
Another factor slowing down the activity of the Ipsen group, the slowdown in growth in emerging countries will lead to a decline of around 3 to 5% in sales of general medicine products in just a few years.
The investments made in the company Octero Pharm will show late effects as well, i.e. not before 2020 in terms of first revenue.
Finally, analysts aren't ruling out a possible financing during the next two years in order to guarantee the development of the Onivyde Company.